[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363968-105":59,"doc-detail-363968-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ultrasensitive-circulating-tumor-dna-detection-improves-prognostication-in-triple-negative-breast-cancer-postneoadjuvant-therapy","Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy","","Ultrasensitive ctDNA testing is evaluated as a sensitive biomarker for patients with stage II to III triple-negative breast cancer (TNBC) receiving neoadjuvant therapy. In a retrospective analysis of 286 plasma samples from 86 patients in the SCANDARE study, ctDNA was measured at baseline, during and after NAT, and during follow-up using a tumor-informed whole-genome assay. After a median 5.1-year follow-up, ctDNA positivity at ultrasensitive levels post-NAT, presurgery showed strong prognostic value for distant recurrence-free interval, disease-free survival, and overall survival, improving risk stratification particularly among non-pCR patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ultrasensitive-circulating-tumor-dna-detection-improves-prognostication-in-triple-negative-breast-cancer-postneoadjuvant-therapy/363968/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ultrasensitive-circulating-tumor-dna-detection-improves-prognostication-in-triple-negative-breast-cancer-postneoadjuvant-therapy/363968.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in early-stage TNBC after neoadjuvant therapy?","Question",{"text":112,"@type":113},"Current guidelines rely on neoadjuvant treatment response, but a critical unmet need is a sensitive test to detect distant micrometastases and personalize postneoadjuvant systemic therapy beyond pathological complete response (pCR).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ctDNA measured, and at what timepoints?",{"text":117,"@type":113},"The study retrospectively analyzed 286 plasma samples from 86 SCANDARE patients and assessed circulating tumor DNA at three presurgical timepoints (baseline, during, and post-NAT) and during postsurgical follow-up when available, using an ultrasensitive tumor-informed whole-genome assay.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main prognostic findings of ultrasensitive ctDNA detection after NAT?",{"text":121,"@type":113},"Ultrasensitive ctDNA detection post-NAT, presurgery was highly prognostic for distant recurrence-free interval, disease-free survival, and overall survival. It also improved prognostication in patients without pCR at surgery, with most non-pCR patients with undetectable ctDNA remaining distant recurrence-free.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363968,1790733613,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ORIGINAL ARTICLE  \nUltrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy  \nL. Cabel1 , 2†, C. Lamy3†, C. W. Abbott4†, K. C. Keough4†, N. Pouget5, J.-Y. Pierga1 , 6, M.-P. Sablin3, J. Flavius3, T. Bronzini7, E. Laas5, L. Darrigues5, B. Li4, F. C. P. Navarro4, J.-G. Féron5, V. Fourchotte5, C. Bonneau5 , 8, A. Vincent-Salomon7 , 9,  \nS. M. Boyle4‡, R. O. Chen4‡, C. Le Tourneau3 , 8 , 10‡ & F.-C. Bidard1 , 2 , 11‡∗  \n1Department of Medical Oncology, Institute Curie, Paris and Saint-Cloud; 2Circulating Tumor Biomarkers Laboratory, CIC Inserm 1428, Paris; 3Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France; 4Personalis, Inc, Fremont, California, USA; 5Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Paris and Saint-Cloud; 6Université Paris Cité, Paris; 7Institut Curie, Department of Theranostic and Diagnostic Medicine, University Paris-Sciences Lettres, Paris; 8Computational Oncology, PSL Research University, Mines Paris Tech, INSERM U1331, Paris; 9INSERM U1339, Institut CURIE, Paris; 10Paris-Saclay University, Paris; 11Versailles Saint Quentin University, Saint-Cloud, France  \nAvailable online xxx  \nBackground: Current treatment guidelines for patients diagnosed with stage II to III triple-negative breast cancer (TNBC) rely on the use of neoadjuvant therapy (NAT) . A critical unmet need is a sensitive test that can inform the presence of distant micrometastases to help personalize postneoadjuvant systemic therapy beyond pathological complete response (pCR) .  \nPatients and methods: In this study, 286 plasma samples from 86 patients from the SCANDARE study were retrospectively analyzed for circulating tumor DNA (ctDNA) at three presurgical timepoints: baseline, during and post-NAT, and during postsurgical follow-up, when available, using an ultrasensitive, tumor-informed, wholegenome-based assay.  \nResults: After a median follow-up of 5.1 years, 15 patients (17 .4%) had developed distant metastases, and 19 patients (22 . 1%) died; 100% of pretreatment baseline plasma samples were positive for detected ctDNA, and the majority of ctDNA detections during and post-NAT, presurgery, were at ultrasensitive (\u003C100 parts per million) levels. Ultrasensitive ctDNA detection post-NAT, presurgery was highly prognostic of distant recurrence-free interval, disease-free survival, and overall survival. Notably, ultrasensitive ctDNA detection status improved the prognostication of patients without pCR at surgery, with 94% of non-pCR patients with undetectable ctDNA post-NAT, presurgery remaining distant recurrence-free.  \nConclusions: These findings highlight the potential of ctDNA to refine risk assessment in patients with early-stage TNBC and support its investigation in interventional settings to guide systemic treatment decisions.  \nKey words: biomarkers, ctDNA, neoadjuvant therapy, TNBC  \nINTRODUCTION  \nThe current standard of care for stage II to III triplenegative breast cancer (TNBC) includes neoadjuvant chemotherapy (NAC), with the recent addition of pembrolizumab.1 The residual cancer burden (RCB) scoring system quantifies post-neoadjuvant treatment (NAT) response,2 stratifying patients into four categories: RCB-0  \n*Correspondence to: Prof. François-Clément Bidard, Institut Curie, 35 rue  \nDailly, 92210, Saint-Cloud, France. Tel: +33147112341 E-mail: francois-clement.bidard@curie.fr (F.-C. Bidard).  \n†These authors contributed equally to this work.  \n‡These authors jointly supervised this work.  \nTwitter handles: Ultrasensitive ctDNA improves risk stratification in early TNBC after NAT.  \n2059-7029/© 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n[pathologic complete","cbCainUQQKqc3hU6","https://ap.wps.com/l/cbCainUQQKqc3hU6","pdf",694695,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What problem does the study address in early-stage TNBC after neoadjuvant therapy?\",\"answer\":\"Current guidelines rely on neoadjuvant treatment response, but a critical unmet need is a sensitive test to detect distant micrometastases and personalize postneoadjuvant systemic therapy beyond pathological complete response (pCR).\"},{\"question\":\"How was ctDNA measured, and at what timepoints?\",\"answer\":\"The study retrospectively analyzed 286 plasma samples from 86 SCANDARE patients and assessed circulating tumor DNA at three presurgical timepoints (baseline, during, and post-NAT) and during postsurgical follow-up when available, using an ultrasensitive tumor-informed whole-genome assay.\"},{\"question\":\"What were the main prognostic findings of ultrasensitive ctDNA detection after NAT?\",\"answer\":\"Ultrasensitive ctDNA detection post-NAT, presurgery was highly prognostic for distant recurrence-free interval, disease-free survival, and overall survival. It also improved prognostication in patients without pCR at surgery, with most non-pCR patients with undetectable ctDNA remaining distant recurrence-free.\"}]","Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy | PDF",1790154619,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c03ab5be8835858f84a0eba00cc22f05.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2e16e86f00875875cc6b6f3279ee70b.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04689fda8fec10032239948c9b49d207.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e9d9ec649b1d8de7459c7701eee96dc.webp",980,1265]